Characteristics of initial irAEs
Retreatment | Discontinuation | P | |
---|---|---|---|
Grade of the first irAE, N (%) | 0.01 | ||
Grades 1 and 2 | 25 (66) | 10 (33) | |
Grades 3 and 4 | 13 (34) | 20 (67) | |
Type of irAE; N (%) | 0.62a | ||
Pneumonitis | 6 (16) | 7 (23) | |
Colitis | 7 (18) | 5 (17) | |
Rash/pruritus | 5 (13) | 6 (20) | |
ALT or AST increase | 3 (8) | 4 (13) | |
Arthralgia/myalgia | 5 (13) | 1 (3) | |
Nephritis | 2 (5) | 2 (7) | |
Pancreatic enzymes elevation | 4 (11) | 0 (0) | |
Meningitis/headache | 2 (5) | 1 (3) | |
Endocrine disordersb | 2 (5) | 1 (3) | |
Ventricular arrhythmias | 1 (3) | 0 (0) | |
Fatigue | 1 (2) | 0 (0) | |
ITP | 0 (0) | 1 (3) | |
Other | 0 (0) | 2 (7) | |
Hospitalizations, N (%) | 8 (21) | 16 (53) | 0.01 |
Time interval to irAE: | |||
Days, median (range) | 69 (14–577) | 73 (2–452) | 0.77 |
No. infusions before the irAE: | |||
No., median (range) | 4.5 (1–42) | 5.5 (1–27) | 0.51 |
Corticosteroid used, N (%) | 29 (76) | 29 (97) | 0.03 |
Intravenous | 3 (10) | 12 (40) | |
Oral | 23 (80) | 16 (53) | |
Otherc | 3 (10) | 2 (6) | |
Steroids > 4 weeks, N (%) | 10 (34) | 15 (65)d | 0.04 |
Anti-TNF used in the first toxicity, N (%) | 0 (0) | 3 (9) | 0.05 |
irAE resolved to, N (%) | 0.03 | ||
Grades 0 and 1 | 37 (97) | 23 (79) | |
Grade ≥ 2 | 1 (3) | 6 (21) | |
Death related to irAE; N (%) | 0 | 2 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ITP, idiopathic thrombocytopenic purpura; Anti-TNF, antitumor necrosis factor alpha.
↵aThis P value refers to the comparison of the four more common toxicities.
↵bHypothyroidism (n = 1), hyperthyroidism (n = 1), and adrenal insufficiency (n = 1).
↵cTopical steroids or nonabsorbable budesonide.
↵dThere are 6 patients who were not evaluable for this category for reasons such as death, loss of follow-up, and noncompliance.